Patent · US Active

Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1

US8541592B2 · kind B2 · utility

3Cited by

4References

11Claims

0Family size

Assignees

AMGEN INC. · US
Biovitrum AB · SE

Inventors

Martin Henriksson · Stockholm, SE
Evert Homan · Sollentuna, SE
Lars Johansson · Bromma, SE
Jerk Vallgarda · Uppsala, SE
Meredith Williams · Singapore, SG
Eric A. Bercot · Bend, US
Christopher H. Fotsch · Thousand Oaks, US
Aiwen Li · Westlake Village, US
Guolin Cai · Guilford, US
Randall W. Hungate · Lansdale, US
Chester Chenguang Yuan · Newbury Park, US
Christopher M. Tegley · Thousand Oaks, US
David J. St. Jean, Jr. · Camarillo, US
Nianhe Han · Newbury Park, US
Qi Huang · Moorpark, US
Qingyian Liu · Camarillo, US
Michael D. Bartberger · West Hollywood, US
George A. Moniz · Cambridge, US
Matthew J. Frizzle · Dundas, CA
Teresa L. Marshall · Stow, US

Key dates

Filing date	Nov 13, 2006
Grant date	Sep 24, 2013
Priority date	—
Expiry date	Jan 24, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to thiazolinones and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-β-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.